数位生物标记市场－全球产业规模、份额、趋势、机会和预测，按成分、类型、治疗领域、最终用户、地区和竞争细分，2020-2030 年预测

2024年，全球数位生物标记市场价值为34.9亿美元，预计在预测期内将实现令人印象深刻的成长，到2030年的复合年增长率将达到14.88%。数位生物标记能够捕捉个人利用数位健康技术主动收集的有关自身健康状况或疾病治疗的资讯。这些资讯可用于解释、影响和预测健康结果。数位生物标记可以收集大量资料，包括睡眠模式、心率变异性、身体活动和认知功能。这些数据透过各种感测器（例如GPS、加速度计和麦克风）收集，并使用先进的演算法和机器学习技术进行分析。

数位生物标记提供了收集事实和有临床价值的资料的机会。它们有助于基本成像能力和提高空间精度。数位生物标记可用于颈动脉导管疾病、胃主动脉瘤、复杂边缘静脉疾病和主动脉分析。在医疗保健领域，数位生物标记是巨量资料发现的主要来源。它们有助于评估当前的健康问题，并预测和评估危险情况。这些设备可作为植入式、便携式、消耗性以及穿戴式装置。透过实现早期疾病识别和诊断、个人化治疗以及提高生活质量，数位生物标记的应用可以改变医疗保健领域。此外，它们为研究人员提供了大量资讯以识别趋势和模式，促进新型疗法和治疗方法的开发。再者，在临床研究中客观且患者参与度最低的资料收集可以提高真实性，从而生产出更精准的药物。

关键市场驱动因素

癌症发生率上升

主要市场挑战

产品成本高

主要市场趋势

数位生物标誌物的使用日益增长以及穿戴式装置和智慧型手机的普及

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球数位生物标记市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按组件（资料收集工具与资料整合系统）
  • 按类型（新型数位生物标记、原始数位生物标记、已批准的数位生物标记）
  • 依治疗领域（心血管疾病、睡眠与运动疾病、神经退化性疾病、精神疾病、其他）
  • 按最终用户（生物技术和製药公司、付款人、提供者、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美数位生物标记市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲数位生物标记市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太数位生物标记市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美数位生物标记市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲数位生物标记市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 13 章：全球数位生物标记市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• ActiGraph, LLC
• AliveCor, Inc.
• Altoida AG
• Biogen Inc.
• Fitbit, Inc.
• HumanAPI Inc.
• Pfizer, Inc.
• Sanofi SA
• Novartis International AG
• Neurotrack Technologies, Inc.

第 16 章：策略建议

第17章调查会社について・免责事项

Global Digital Biomarkers Market was valued at USD 3.49 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 14.88% through 2030. Digital biomarkers capture information that individuals actively gather about their own well-being or the treatment of a condition using digital health technology. This information is used to explain, influence, and predict health outcomes. Digital biomarkers can collect extensive data, including sleep patterns, heart rate variability, physical activity, and cognitive function. They are collected through various sensors, such as GPS, accelerometers, and microphones, and analyzed using advanced algorithms and machine learning techniques.

Digital biomarkers provide an opportunity to gather factual and clinically valuable data. They contribute to essential imaging capabilities and improved spatial accuracy. Digital biomarkers offer services for carotid conduit disease, stomach aortic aneurysm, complicated fringe vein disease, and aortic analysis. In the healthcare sector, digital biomarkers are the primary source of big data findings. They help evaluate current health issues, as well as predict and assess dangerous scenarios. These devices are available as implanted, portable, consumable, and wearable items. By enabling early disease identification and diagnosis, individualized therapies, and enhancing the quality of life, the application of digital biomarkers can transform the healthcare sector. Additionally, they provide researchers with a wealth of information to identify trends and patterns, facilitating the development of novel cures and treatments. Furthermore, the objective and minimally patient-involved data acquisition in clinical studies can enhance authenticity, leading to the production of more precise medications.

Key Market Drivers

Rise in Prevalence of Cancers

The worldwide pervasiveness of smoking, physical inactivity, and unhealthy food habits significantly influences the incidence of cancer. These habits, when combined, create an environment that promotes the development and progression of cancerous cells within the body. To this end, biomarkers play a crucial role in enabling constant tracking and monitoring of diverse characteristics regarding health and diseases. By measuring specific molecules or genetic alterations, biomarkers provide valuable insights into the underlying mechanisms of cancer development.

The multistage carcinogenesis process involves a series of molecular pathway events that eventually lead to the development of cancer. From the initial genetic mutations to the formation of a tumor, each step in this process contributes to the progression of the disease. Understanding these molecular events is essential for early detection, accurate diagnosis, and effective treatment of cancer. However, the diagnosis, prognosis, and therapy of cancer can be quite complex. Each cancer type differs from other forms based on its unique molecular profile, making it challenging to develop standardized approaches for treatment. This complexity necessitates the need for advanced technologies and innovative solutions to deliver personalized and precise care to patients.

In recent years, the concept of digital biomarkers has emerged as a promising avenue for better analysis and insights into patients' health. These digital biomarkers, collected through various digital health technologies such as wearable devices and mobile applications, provide continuous monitoring of individuals' health parameters. By capturing real-time data on vital signs, physical activity, sleep patterns, and other relevant indicators, digital biomarkers offer a comprehensive view of an individual's health status.

The increasing demand for personalized medicine and the growing adoption of digital health technologies have fueled the growth of the global digital biomarkers market. With the ability to provide objective and quantifiable data, digital biomarkers have opened up numerous opportunities for improving disease management and enhancing patient outcomes. This, in turn, has led to abundant growth in the field, with researchers, healthcare providers, and technology companies actively exploring the potential of digital biomarkers in transforming the future of healthcare.

Key Market Challenges

High Product Cost

The emerging field of digital biomarkers holds great promise for revolutionizing healthcare by providing valuable insights into patients' health and facilitating early disease detection. However, a significant obstacle to the widespread adoption of digital biomarkers is the high product cost associated with their development and implementation. This cost factor poses several challenges to the demand for digital biomarkers in healthcare. The high product cost of digital biomarkers affects their affordability for both healthcare providers and patients. The research, development, and validation processes for digital biomarkers involve substantial investments in technology, data collection, analytics, and regulatory compliance. These costs can translate into expensive licensing fees for healthcare institutions, limiting their ability to integrate these biomarkers into routine patient care.

The financial burden of high-cost digital biomarkers may deter healthcare organizations from investing in the necessary infrastructure and training required for their implementation. Smaller or underfunded healthcare facilities, in particular, may struggle to allocate resources to adopt these advanced technologies, leading to disparities in access to cutting-edge healthcare solutions. Additionally, the high product cost of digital biomarkers may result in higher healthcare expenses for patients. As the cost of implementing and utilizing these biomarkers is passed on to consumers, it could potentially discourage individuals from seeking out and utilizing these technologies, particularly in regions with limited healthcare coverage or insurance.

Key Market Trends

Growing Use of Digital Biomarkers and Penetration of Wearable Devices and Smartphones

The growing utilization of digital biomarkers in diabetes, respiratory diseases, cardiovascular diseases, and sleep disorders serves as a significant driver in the market. The adoption of handheld and wearable digital devices, which constitute a substantial portion of the digital biomarker market, has been facilitated by digital technologies. Health informatics is expanding the global market for digital biomarkers, enabling personalized and cost-effective care. Furthermore, the rapid evolution of telecommunications and IT infrastructure is fueling the demand for digital biomarkers. With increasing investments in healthcare digitalization and smart hospitals by governments and corporations, the global demand for digital biomarkers is expected to witness a boost.

Wearable devices, following Bluetooth headsets, rank as the industry's second-largest innovation. In healthcare, devices such as Google Glass, Apple Watch, Fitbit, MotivRing, and Oculus Rift are widely used. The growing prevalence of wearable devices in healthcare can be attributed to the rising global health awareness, increasing patient population, and the integration of technology into daily life. Numerous apps available on Google Play and iOS platforms monitor sleep, heart rate, and movement. A recent survey revealed that smartphones are utilized in 80% of developed countries and 82% of developing countries.

Key Market Players

• ActiGraph, LLC
• AliveCor, Inc.
• Altoida AG
• Biogen Inc.
• Fitbit, Inc.
• HumanAPI Inc.
• Pfizer, Inc.
• Sanofi S.A.
• Novartis International AG
• Neurotrack Technologies, Inc.

Report Scope:

In this report, the Global Digital Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Digital Biomarkers Market, By Component:

• Data Collection Tools
  • Digital Platforms
  • Mobile Apps
  • Desktop-Based Software
  • Wearable
  • Others
• Data Integration Systems

Digital Biomarkers Market, By Type:

• Novel Digital Biomarkers
• Original Digital Biomarkers
• Approved Digital Biomarkers

Digital Biomarkers Market, By Therapeutic Area:

• Cardiovascular Diseases
• Sleep & Movement Diseases
• Neurodegenerative Disorders
• Psychiatric Disorder
• Others

Digital Biomarkers Market, By End User:

• Biotechnology & Pharmaceutical Companies
• Payers
• Providers
• Others

Digital Biomarkers Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Digital Biomarkers Market.

Available Customizations:

Global Digital Biomarkers market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Digital Biomarkers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Component (Data Collection Tools v/s Data Integration Systems)
    • 5.2.1.1. Data Collection Tools {Digital Platforms, Mobile Apps, Desktop-Based Software, Wearable, Others}
  • 5.2.2. By Type (Novel Digital Biomarkers, Original Digital Biomarkers, Approved Digital Biomarkers)
  • 5.2.3. By Therapeutic Area (Cardiovascular Diseases, Sleep & Movement Diseases, Neurodegenerative Disorders, Psychiatric Disorder, Others)
  • 5.2.4. By End User (Biotechnology & Pharmaceutical Companies, Payers, Providers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Digital Biomarkers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component
  • 6.2.2. By Type
  • 6.2.3. By Therapeutic Area
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Digital Biomarkers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Component
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Therapeutic Area
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Digital Biomarkers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Component
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Therapeutic Area
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Digital Biomarkers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Component
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Therapeutic Area
      • 6.3.3.2.4. By End User

7. Europe Digital Biomarkers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Type
  • 7.2.3. By Therapeutic Area
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Digital Biomarkers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Therapeutic Area
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Digital Biomarkers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Therapeutic Area
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Digital Biomarkers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Therapeutic Area
      • 7.3.3.2.4. By End User
  • 7.3.4. France Digital Biomarkers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Component
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Therapeutic Area
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Digital Biomarkers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Component
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Therapeutic Area
      • 7.3.5.2.4. By End User

8. Asia-Pacific Digital Biomarkers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Type
  • 8.2.3. By Therapeutic Area
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Digital Biomarkers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Therapeutic Area
      • 8.3.1.2.4. By End User
  • 8.3.2. India Digital Biomarkers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Therapeutic Area
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Digital Biomarkers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Therapeutic Area
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Digital Biomarkers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Therapeutic Area
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Digital Biomarkers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Therapeutic Area
      • 8.3.5.2.4. By End User

9. South America Digital Biomarkers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Type
  • 9.2.3. By Therapeutic Area
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Digital Biomarkers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Therapeutic Area
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Digital Biomarkers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Therapeutic Area
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Digital Biomarkers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Therapeutic Area
      • 9.3.3.2.4. By End User

10. Middle East and Africa Digital Biomarkers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Type
  • 10.2.3. By Therapeutic Area
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Digital Biomarkers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Therapeutic Area
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Digital Biomarkers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Therapeutic Area
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Digital Biomarkers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Therapeutic Area
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Digital Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. ActiGraph, LLC
  • 15.1.1. Business Overview
  • 15.1.2. Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AliveCor, Inc.
• 15.3. Altoida AG
• 15.4. Biogen Inc.
• 15.5. Fitbit, Inc.
• 15.6. HumanAPI Inc.
• 15.7. Pfizer, Inc.
• 15.8. Sanofi S.A.
• 15.9. Novartis International AG
• 15.10. Neurotrack Technologies, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer